Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from a main source of production, namely CD64-positive myelocytes. As the treatment landscape of IL-23–targeted therapies continues to expand, it is crucial that gastroenterology clinicians understand the differentiating aspects of current and emerging treatments in order to develop an efficacious, lasting, and individualized treatment plan for each patient.
In this CME Outfitters recorded symposium, expert faculty will review the functions of Fc gamma receptors, CD64 and its connection with IL-23, the molecular attributes of anti–IL-23 therapies, in vivo data on expression of CD64 monocytes, and the most recent clinical trial data differentiating the anti–IL-23 agents. To demonstrate these concepts, animated 3-D models will be included in the educational program and available to attendees.
At the conclusion of this activity, learners will be able to better:
This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.- both are Johnson & Johnson companies.
Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), and nurses
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.50 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 12/28/2024. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Dubinsky reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Celltrion Inc.; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; Spyre Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Other financial or material support: (PI) Janssen Biotech, Inc. Road to Prevention; (Co-PI) Helmsley Foundation PK Dashboard Optimized Dosing of Infliximab Is Not Inferior to Standard Reactive Dosing: The OPTIMIZE Trial
Dr. Hudesman reports the following financial relationships:
Consultant: AbbVie Inc.; Avalo Therapeutics, Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Fresenius Kabi; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Janssen Pharmaceuticals, Inc. and Pfizer Inc.
Dr. Siegel reports the following financial relationships:
Advisory Board: AbbVie Inc.; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Lilly; Napo Therapeutics; Pfizer Inc.; Prometheus Biosciences, Inc.; Roivant Sciences; Takeda Pharmaceuticals U.S.A., Inc.; and Trellus Health Inc.
Consultant: AbbVie Inc.; Boomerang; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Pfizer Inc; Prometheus Biosciences, Inc.; Prometheus Labs; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer Inc.
Other financial or material support: Dr. Corey Siegel is co-founder of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.
The following individuals have no financial relationships to disclose:
Jeffrey Helfand, DO (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 877.CME.PROS (877.263.7767).
MMV-142-110424-01
